...
首页> 外文期刊>Neural regeneration research >The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis
【24h】

The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis

机译:下一代鞘氨醇-1受体调节剂BAF312(siponimod)改善局灶性自身免疫性脑脊髓炎的皮质网络功能

获取原文
           

摘要

Autoimmune diseases of the central nervous system (CNS) like multiple sclerosis (MS) are characterized by inflammation and demyelinated lesions in white and grey matter regions. While inflammation is present at all stages of MS, it is more pronounced in the relapsing forms of the disease, whereas progressive MS (PMS) shows significant neuroaxonal damage and grey and white matter atrophy. Hence, disease-modifying treatments beneficial in patients with relapsing MS have limited success in PMS. BAF312 (siponimod) is a novel sphingosine-1-phosphate receptor modulator shown to delay progression in PMS. Besides reducing inflammation by sequestering lymphocytes in lymphoid tissues, BAF312 crosses the blood-brain barrier and binds its receptors on neurons, astrocytes and oligodendrocytes. To evaluate potential direct neuroprotective effects, BAF312 was systemically or locally administered in the CNS of experimental autoimmune encephalomyelitis mice with distinct grey- and white-matter lesions (focal experimental autoimmune encephalomyelitis using an osmotic mini-pump). Ex-vivo flow cytometry revealed that systemic but not local BAF312 administration lowered immune cell infiltration in animals with both grey and white matter lesions. Ex-vivo voltage-sensitive dye imaging of acute brain slices revealed an altered spatio-temporal pattern of activation in the lesioned cortex compared to controls in response to electrical stimulation of incoming white-matter fiber tracts. Here, BAF312 administration showed partial restore of cortical neuronal circuit function. The data suggest that BAF312 exerts a neuroprotective effect after crossing the blood-brain barrier independently of peripheral effects on immune cells. Experiments were carried out in accordance with German and EU animal protection law and approved by local authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen; 87-51.04.2010.A331) on December 28, 2010.
机译:中枢神经系统(CNS)的自身免疫性疾病(如多发性硬化症(MS))的特征是白质和灰质区的炎症和脱髓鞘病变。尽管炎症在MS的所有阶段均存在,但在疾病的复发形式中更为明显,而进行性MS(PMS)显示出明显的神经轴索损伤以及灰白质萎缩。因此,对复发性MS患者有益的疾病缓解疗法在PMS中的成功有限。 BAF312(siponimod)是一种新型的鞘氨醇-1-磷酸受体调节剂,显示可延迟PMS的进程。除了通过隔离淋巴样组织中的淋巴细胞来减少炎症外,BAF312还穿过血脑屏障并将其受体结合在神经元,星形胶质细胞和少突胶质细胞上。为了评估潜在的直接神经保护作用,将BAF312全身或局部施用于实验性自身免疫性脑脊髓炎小鼠的中枢神经系统疾病,该小鼠具有明显的灰色和白色物质病变(使用渗透微型泵进行的实验性自身免疫性脑脊髓炎)。体外流式细胞术显示全身性而非局部性BAF312施用降低了灰白病患者的免疫细胞浸润。响应于传入的白质纤维束的电刺激,与对照组相比,急性脑切片的离体电压敏感染料成像显示病变皮层中激活的时空模式发生了变化。在这里,BAF312给药显示皮质神经元回路功能的部分恢复。数据表明,BAF312穿过血脑屏障后会发挥神经保护作用,而与免疫细胞的外围作用无关。实验是根据德国和欧盟的动物保护法进行的,并于2010年12月28日获得地方政府的批准(LandesamtfürNatur,Umwelt和Verbraucherschutz Nordrhein-Westfalen; 87-51.04.2010.A331)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号